-transparent.png){kind=logo}
1 Fifty-seven elderly patients with primary osteoarthritis of the hip and knee were entered into a double-blind, randomized, controlled parallel group trail to compare the efficacy and tolerability of isoxicam (maximum = 200 mg day-1) and piroxicam (maximum = 20 mg day-1). 2 Clinical assessments were made following a 1 week NSAID-free washout period and at biweekly intervals during the next 6 weeks of active treatment. 3 The majority of patients in both groups experienced a clinically important and statistically significant therapeutic response. 4 No statistically significant between-group differences were noted with respect to drug efficacy. 5 One patient was withdrawn from the piroxicam group because of lack of effect, but there were no such withdrawals from the isoxicam group. 6 Five patients were withdrawn from the piroxicam group because of adverse reactions compared to only one withdrawal from the isoxicam group. 7 This study indicates that isoxicam is an efficacious and well-tolerated once-daily NSAID for elderly patients with osteoarthritis.
N Bellamy, and
W W Buchanan, and
E Grace
November 1987,
The American journal of medicine,
N Bellamy, and
W W Buchanan, and
E Grace
January 1981,
The British journal of clinical practice,
N Bellamy, and
W W Buchanan, and
E Grace
October 2004,
Arthritis and rheumatism,
N Bellamy, and
W W Buchanan, and
E Grace
January 2003,
Clinical and experimental rheumatology,
N Bellamy, and
W W Buchanan, and
E Grace
February 1992,
Annals of the rheumatic diseases,
N Bellamy, and
W W Buchanan, and
E Grace
November 2017,
Iranian journal of medical sciences,
N Bellamy, and
W W Buchanan, and
E Grace
January 1998,
West African journal of medicine,
N Bellamy, and
W W Buchanan, and
E Grace
January 2009,
Arthritis research & therapy,
N Bellamy, and
W W Buchanan, and
E Grace
January 1985,
The Journal of international medical research,
N Bellamy, and
W W Buchanan, and
E Grace
November 2014,
Phytotherapy research : PTR,
